266 related articles for article (PubMed ID: 33835767)
1. Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension.
Feng B; Zhang D; Wang Q; Yu F; Zou Q; Xie G; Wang R; Yang X; Chen W; Lou B; Zheng S; Chen Y
J Zhejiang Univ Sci B; 2021 Apr; 22(4):330-340. PubMed ID: 33835767
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
3. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
4. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
[TBL] [Abstract][Full Text] [Related]
5. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
[TBL] [Abstract][Full Text] [Related]
6. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
8. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
Choksi TT; Zhang H; Chen T; Malhotra N
Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
[TBL] [Abstract][Full Text] [Related]
10. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
11. [Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
Huang W; Li T; Ling Y; Qian ZP; Zhang YY; Huang D; Xu SB; Liu XH; Xia L; Yang Y; Lu SH; Lu HZ
Zhonghua Nei Ke Za Zhi; 2020 Sep; 59(9):689-694. PubMed ID: 32838499
[No Abstract] [Full Text] [Related]
12. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
[TBL] [Abstract][Full Text] [Related]
13. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
[TBL] [Abstract][Full Text] [Related]
14. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
[TBL] [Abstract][Full Text] [Related]
15. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension.
Kuzeytemiz M; Tenekecioglu E
J Investig Med; 2022 Mar; 70(3):786-791. PubMed ID: 34987107
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
[TBL] [Abstract][Full Text] [Related]
18. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
[TBL] [Abstract][Full Text] [Related]
19. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19.
Soleimani A; Kazemian S; Karbalai Saleh S; Aminorroaya A; Shajari Z; Hadadi A; Talebpour M; Sadeghian H; Payandemehr P; Sotoodehnia M; Bahreini M; Najmeddin F; Heidarzadeh A; Zivari E; Ashraf H
Am J Hypertens; 2020 Dec; 33(12):1102-1111. PubMed ID: 32920644
[TBL] [Abstract][Full Text] [Related]
20. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
